{
  "meta": {
    "title": "61_Respiratory_System",
    "url": "https://brainandscalpel.vercel.app/61-respiratory-system-134b34dd.html",
    "scrapedAt": "2025-11-30T12:34:39.951Z"
  },
  "questions": [
    {
      "text": "Which of the following is a long-acting β-2 agonist that can be prescribed in a patient with moderately severe bronchial asthma?",
      "choices": [
        {
          "id": 1,
          "text": "Salbutamol"
        },
        {
          "id": 2,
          "text": "Indacaterol"
        },
        {
          "id": 3,
          "text": "Terbutaline"
        },
        {
          "id": 4,
          "text": "Formoterol"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Formoterol </strong>is a <strong>long-acting &beta;-2 agonist</strong>&nbsp;(LABA).</p>\n<p>Beta 2 agonists are classified based on their duration of action into:&nbsp;</p>\n<ul>\n<li>Short-acting &beta;<strong>-</strong>2 agonists (<strong>SABA</strong>):\n<ul>\n<li>Salbutamol</li>\n<li>Terbutaline&nbsp;</li>\n<li>Pirbuterol</li>\n</ul>\n</li>\n<li>Long-acting &beta;<strong>-</strong>2 agonists (<strong>LABA</strong>):\n<ul>\n<li>Salmeterol</li>\n<li>Formoterol</li>\n</ul>\n</li>\n<li>Very long-acting &beta;<strong>-</strong>2 agonists (<strong>V-LABA</strong>):\n<ul>\n<li>Indacaterol</li>\n<li>Olodaterol</li>\n<li>Vilanterol</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8702",
      "difficulty": "easy"
    },
    {
      "text": "What is the current GINA recommendation for the prescription of long-acting β-2 agonists in patients suffering from bronchial asthma?",
      "choices": [
        {
          "id": 1,
          "text": "As monotherapy"
        },
        {
          "id": 2,
          "text": "In combination with an inhaled anticholinergic"
        },
        {
          "id": 3,
          "text": "In combination with an inhaled corticosteroid"
        },
        {
          "id": 4,
          "text": "In combination with a short acting β-2 agonist"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>LABA</strong> is used in <strong>combination </strong>with<strong> inhalational corticosteroids</strong>&nbsp;(ICS),<strong>&nbsp;</strong>preferably in the form of a combination inhaler.</p>\n<p>LABA is never taken alone as it does not treat the underlying chronic inflammation of asthma. Corticosteroids&nbsp;will decrease the underlying inflammation and halt the progression of the disease.</p>\n<p>Short-acting &beta;-2 agonists (<strong>SABA</strong>) can be given as an add-on therapy to the LABA-ICS combination (<strong>as-needed therapy</strong>).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8707",
      "difficulty": "easy"
    },
    {
      "text": "Which among the following is the most appropriate therapy for bronchodilation in acute severe asthma?",
      "choices": [
        {
          "id": 1,
          "text": "Intravenous aminophylline"
        },
        {
          "id": 2,
          "text": "Inhalational anticholinergics"
        },
        {
          "id": 3,
          "text": "Nebulized SABA"
        },
        {
          "id": 4,
          "text": "Intravenous SABA"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Nebulized short-acting beta-2 agonists</strong> (SABAs) are the most appropriate therapy in <strong>acute severe asthma</strong> among the given options. </p>\n<p><strong>Nebulized route </strong>is preferred over the intravenous route as it is <strong>easier</strong> and<strong> safer </strong>with equivalent efficacy.</p>\n<p>Intravenous aminophylline is less effective than SABA and is reserved for those who are resistant or intolerant to beta-2 agonists with acute severe asthma. </p>\n<p>Inhalational anticholinergics are not indicated in acute severe asthma as they are less effective than SABAs.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4382",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not a side effect of salbutamol?",
      "choices": [
        {
          "id": 1,
          "text": "Hypoglycemia"
        },
        {
          "id": 2,
          "text": "Hypokalemia"
        },
        {
          "id": 3,
          "text": "Tremors"
        },
        {
          "id": 4,
          "text": "Tachycardia"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Hypoglycemia is not a side effect of <strong>salbutamol</strong>. It causes <strong>hyperglycemia.</strong></p>\n<p>The side effects of salbutamol are due to the <strong>stimulation</strong> of <strong>extrapulmonary β<sub>2 </sub>receptors. </strong>They are more common after oral or intravenous<strong> </strong>administration. The side effects seen are:    </p>\n<ul>\n<li>Muscle tremor</li>\n<li>Tachycardia</li>\n<li>Hypokalemia </li>\n<li>Restlessness        </li>\n<li>Hypoxemia         </li>\n<li>Increase in free fatty acid, insulin, glucose, pyruvate, and lactate</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3492",
      "difficulty": "easy"
    },
    {
      "text": "An asthmatic patient complains of wheezing and shortness of breath most days of the week. Which of the following therapies is preferred in him?",
      "choices": [
        {
          "id": 1,
          "text": "Inhaled SABA"
        },
        {
          "id": 2,
          "text": "Inhaled LABA"
        },
        {
          "id": 3,
          "text": "Inhaled  LABA + inhaled corticosteroids"
        },
        {
          "id": 4,
          "text": "Inhaled SABA + inhaled corticosteroids"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p class=\"p1\">This patient has&nbsp;<strong>persistent asthma </strong>for which<strong>&nbsp;</strong>the preferred therapy<strong>&nbsp;</strong>is<strong>&nbsp;LABA with ICS </strong>available as a<strong>&nbsp;combination inhaler.</strong></p>\n<p>ICS should be started in any patient who needs to use a short-acting beta-2 agonist inhaler for symptomatic control more than twice a week (persistent asthma).&nbsp;</p><hr><h3>Related Pearl: Treatment of Asthma based on severity of symptoms (GINA-2022)</h3><p>Asthma management - GINA 2022</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3349e17dd3a64530b8cda3c9732af613x1280x3702.792665726375.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4390",
      "difficulty": "easy"
    },
    {
      "text": "A 5-year-old child requires bronchodilator therapy. You attach the device shown below to the pressurized metered-dose inhaler for ease of use. Which of the following is false about this device?",
      "choices": [
        {
          "id": 1,
          "text": "Decreases the deposition of drug on the oropharynx"
        },
        {
          "id": 2,
          "text": "Increases the delivery of drug to lower airways"
        },
        {
          "id": 3,
          "text": "Increases the incidence of oropharyngeal candidiasis"
        },
        {
          "id": 4,
          "text": "Systemic absorption of drugs is unaffected"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given image is of a <strong>spacer device</strong>. It <strong>decreases</strong> the incidence of oropharyngeal <strong>candidiasis</strong> and other&nbsp;propellant-mediated oropharyngeal adverse effects like <strong>dysphonia</strong> that occur with the use of a pMDI.</p>\n<p>Spacers reduce the velocity and size of particles entering the upper airways.&nbsp;This<strong>&nbsp;reduces</strong> the <strong>amount</strong> of drug that impinges on the<strong> oropharynx</strong> and <strong>increases </strong>the proportion of<strong> drug</strong> inhaled into <strong>lower airways.</strong> The <strong>systemic absorption</strong> is <strong>unchanged</strong> by the use of a spacer.</p>\n<p>Spacer devices are <strong>useful</strong> in delivering inhaled drugs to <strong>children</strong>&nbsp;who are not able to use a pMDI alone but can also be used by <strong>adults</strong> for better drug delivery. The image below shows the use of a spacer device with a face mask which is preferred in children younger than 3 years of age.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e51d99cce336454585713400e71a010cx720x540.JPEG\" alt=\"Explanation Image\"><p>The various devices used for the delivery of inhalational drugs are:</p>\n<ul>\n<li><strong>Pressurized metered-dose inhalers -</strong>&nbsp;Drugs are propelled from a canister in the pMDI with the aid of a propellant. These devices are convenient, portable, and typically deliver 50&ndash;200 doses of a drug</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/cf3ec9228e96415da2ec3c3932577099x596x600.JPEG\" alt=\"Explanation Image\"><ul>\n<li><strong>Dry powder inhalers -&nbsp;</strong>these devices scatter the drug into a fine powder that is dispersed by air turbulence on inhalation. DPIs have been developed to deliver drugs such as insulin, but the dosing is inconsistent.&nbsp;Children &lt;7 years find it difficult to use a DPI.&nbsp;</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/3fe2da00a2b7445d8a99ec027efeab5ax799x533.JPEG\" alt=\"Explanation Image\"><ul>\n<li><strong>Nebulizers:</strong>&nbsp;Two types of nebulizer are available -\n<ul>\n<li><strong>Jet nebulizers</strong>&nbsp;that are driven by a stream of gas (air or oxygen)</li>\n<li><strong>Ultrasonic nebulizers</strong>&nbsp;that use a rapidly vibrating piezoelectric crystal and thus do not require a source of compressed gas.</li>\n</ul>\n</li>\n</ul>\n<p>The nebulizers deliver much <strong>higher drug doses</strong> as compared pMDIs. These are useful in:</p>\n<ul>\n<li>Treating acute exacerbations of asthma and COPD</li>\n<li>Extreme airway obstruction (severe COPD)</li>\n<li>Delivering inhaled drugs to infants and small children who cannot use the other inhalation devices</li>\n<li>Administering drugs such as antibiotics in relatively high doses</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2687fee5df024653908a0728befd85afx1024x683.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/c79df03efd6d4a87baad5dad87dd05de.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4389",
      "difficulty": "medium"
    },
    {
      "text": "An asthmatic patient has been taking theophylline tablets for symptomatic relief. On which of the following receptors does this drug have an antagonistic action?",
      "choices": [
        {
          "id": 1,
          "text": "Histamine receptors"
        },
        {
          "id": 2,
          "text": "Bradykinin receptors"
        },
        {
          "id": 3,
          "text": "Adenosine receptors"
        },
        {
          "id": 4,
          "text": "Kallikrein receptors"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Theophylline</strong>&nbsp;has an<strong> antagonistic </strong>action on<strong> adenosine receptors.</strong></p>\n<p>Theophylline is a <strong>methylxanthine.&nbsp;</strong>It acts as a&nbsp;<strong>non-selective PDE inhibitor</strong>. Its other actions include:&nbsp;</p>\n<ul>\n<li>Increased IL-10 release</li>\n<li>Decrease in gene transcription of pro-inflammatory cytokines</li>\n<li>Promotes apoptosis of granulocytes</li>\n<li>Histone deacetylase activation.&nbsp;The recruitment of histone deacetylase-2 by glucocorticoid receptors switches off inflammatory genes. Through this mechanism, theophylline <strong>enhances </strong>the <strong>anti-inflammatory effects</strong> of<strong> corticosteroids</strong>.</li>\n</ul>\n<p>Theophylline can be used as a <strong>bronchodilator</strong> in an <strong>asthmatic</strong> patient on ICS as an <strong>add-on</strong> drug. LABAs are more effective but theophylline is a <strong>cheaper</strong> option.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8714",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements about theophylline is not correct?",
      "choices": [
        {
          "id": 1,
          "text": "Increase in dose is required in cardiopulmonary disease"
        },
        {
          "id": 2,
          "text": "Decreases the breakdown of cAMP in smooth muscles"
        },
        {
          "id": 3,
          "text": "Increase in dose is required in smokers"
        },
        {
          "id": 4,
          "text": "Is a non-selective phosphodiesterase inhibitor"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>A <strong>decrease</strong> in<strong> dose</strong>&nbsp;of theophylline is required in <strong>cardiopulmonary</strong> disease.&nbsp;This is because<strong> reduced clearance </strong>of theophylline is seen in liver disease, pneumonia, and heart failure.</p>\n<p>In smokers, <strong>clearance </strong>of theophylline is<strong> increased</strong> due to the <strong>induction of CYP1A2</strong> enzyme.&nbsp;</p>\n<p>Theophylline is a <strong>non-selective</strong> phosphodiesterase inhibitor that <strong>decreases</strong> the <strong>breakdown of cAMP</strong> levels in smooth muscles resulting in bronchodilation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8729",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is an indication for theophylline?",
      "choices": [
        {
          "id": 1,
          "text": "Supraventricular tachycardia"
        },
        {
          "id": 2,
          "text": "Epilepsy"
        },
        {
          "id": 3,
          "text": "Acute severe asthma"
        },
        {
          "id": 4,
          "text": "Apnea of prematurity"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Theophylline</strong> is indicated in the treatment of <strong>apnea of prematurity</strong>.</p>\n<p>In apnea of prematurity, methylxanthines such as theophylline and caffeine <strong>increase</strong> the <strong>central respiratory drive</strong> by lowering the threshold of response to hypercapnia. They also enhance the contractility of the diaphragm and prevent diaphragmatic fatigue.</p>\n<p>Options A &amp; B - The adenosine receptor antagonism property of theophylline <strong>precipitates </strong>cardiac<strong> arrhythmias </strong>and epileptic<strong> seizures</strong>.&nbsp;</p>\n<p>Option C - Theophylline is <strong>no longer recommended</strong> as a treatment for <strong>acute severe asthma</strong> by the latest guidelines (GINA 2021) because of its poor efficacy and safety profile.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4387",
      "difficulty": "hard"
    },
    {
      "text": "A patient with severe persistent asthma continues to have symptoms despite being on high-dose ICS-LABA therapy. Which of the following is a leukotriene receptor antagonist, appropriate as an add-on therapy for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Dupilumab"
        },
        {
          "id": 2,
          "text": "Roflumilast"
        },
        {
          "id": 3,
          "text": "Zafirlukast"
        },
        {
          "id": 4,
          "text": "Zileuton"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Zafirlukast </strong>and montelukast are <strong>leukotriene receptor antagonists</strong>. They are competitive antagonists of the cysLT1 receptors. These drugs act by:&nbsp;</p>\n<ul>\n<li>Decreasing bronchoconstriction</li>\n<li>Reducing airway mucus secretion</li>\n<li>Decreasing vascular permeability and</li>\n<li>Reducing eosinophil chemotaxis&nbsp;</li>\n</ul>\n<p>Option A: Dupilumab is an interleukin-4 receptor antagonist used in severe asthma.&nbsp;</p>\n<p>Option B: Roflumilast is a PDE-4 selective inhibitor used in the treatment of COPD.</p>\n<p>Option D: Zileuton is a lipoxygenase inhibitor that can be used in the treatment of asthma.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8736",
      "difficulty": "easy"
    },
    {
      "text": "The use of which of the following therapies for acute asthma requires serial monitoring of liver function tests?<div class='question-desc-html'><ol>\n<li>Zileuton</li>\n<li>Salbutamol</li>\n<li>Salmeterol</li>\n<li>Zafirlukast</li>\n<li>Montelukast</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "3 and 4"
        },
        {
          "id": 2,
          "text": "2 and 3"
        },
        {
          "id": 3,
          "text": "1, 2 and 5"
        },
        {
          "id": 4,
          "text": "1, 4 and 5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Zileuton, montelukast,&nbsp;</strong>and<strong> zafirlukast </strong>are all associated with rare instances of<strong> hepatic dysfunction.&nbsp;&nbsp;</strong>Liver function tests should be monitored during the course of their therapy.</p>\n<p>Therapy with selective &beta;-2 agonists (salbutamol, salmeterol) does not require serial monitoring of LFTs.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4377",
      "difficulty": "medium"
    },
    {
      "text": "An elderly asthmatic on treatment presented with fever, malaise, and lower limb sensory deficit. Significant investigations are given below. Which of the following drugs is associated with these findings?<div class='question-desc-html'><ul>\n<li>CBC: eosinophilia</li>\n<li>HRCT chest: bilateral ground-glass attenuation</li>\n<li>Bronchoalveolar lavage: 14.6% eosinophils&nbsp;</li>\n<li>Nasal mucosa biopsy: granulomas&nbsp;</li>\n<li>Serum p-ANCA: positive&nbsp;</li>\n</ul></div>",
      "choices": [
        {
          "id": 1,
          "text": "Montelukast"
        },
        {
          "id": 2,
          "text": "Cromolyn sodium"
        },
        {
          "id": 3,
          "text": "Theophylline"
        },
        {
          "id": 4,
          "text": "Ketotifen"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given scenario points towards a diagnosis of <strong>Churg-Strauss syndrome</strong>. It is an <strong>eosinophilic vasculitis</strong>&nbsp;associated with the use of <strong>montelukast </strong>and zafirlukast. This is a very <strong>rare</strong>ly reported side effect of these drugs.</p>\n<p>These agents <strong>block</strong> the effects of the <strong>cysLTs</strong> (LTC4, LTD4, and LTE4) but they do not block the effect of LTB4, which is a chemoattractant for eosinophils and neutrophils. This can lead to eosinophilia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8774",
      "difficulty": "medium"
    },
    {
      "text": "An asthmatic patient was brought to the ER in an agitated state. His respiratory rate was 32/min and pulse was 124/min. Pulse oximetry revealed a SpO2 of 88% on room air. Which of the following drugs is not useful in this scenario?",
      "choices": [
        {
          "id": 1,
          "text": "Salbutamol"
        },
        {
          "id": 2,
          "text": "Hydrocortisone"
        },
        {
          "id": 3,
          "text": "Cromolyn sodium"
        },
        {
          "id": 4,
          "text": "Ipratropium bromide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario is suggestive of&nbsp;<strong>acute severe asthma</strong>&nbsp;and cromolyn sodium is not useful in its treatment. It is <strong>indicated only</strong> for<strong> chronic prophylaxis.</strong></p>\n<p>Short-acting beta 2 agonists (<strong>SABA</strong>) and<strong> intravenous hydrocortisone</strong> are used in the treatment of acute severe asthma.</p>\n<p><strong>Ipratropium bromide</strong> can also be given in severe asthma exacerbations. It&nbsp;should be given after beta 2-agonists as they have a slower onset of bronchodilatory action.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8737",
      "difficulty": "medium"
    },
    {
      "text": "Omalizumab is added as a step-up therapy in a child with severe asthma, refractory to treatment. Which of the following is true about this drug?",
      "choices": [
        {
          "id": 1,
          "text": "Is administered intravenously"
        },
        {
          "id": 2,
          "text": "Has anti interleukin-5 action"
        },
        {
          "id": 3,
          "text": "Is indicated in acute severe asthma"
        },
        {
          "id": 4,
          "text": "Is a monoclonal antibody against IgE"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Omalizumab</strong> is&nbsp;a monoclonal <strong>antibody against IgE.</strong></p>\n<p>It is used only in patients with <strong>very severe asthma</strong> (not acute severe asthma) who show poor symptom control even with step 4/5 measures as per GINA 2021 guidelines.</p>\n<p>It can only be given to patients aged<strong> &ge;6 years</strong>. It neutralizes circulating IgE and inhibits mast cell degranulation caused by IgE. It is administered <strong>subcutaneously</strong>.</p>\n<p>Another drug used in severe asthma is <strong>mepolizumab</strong>. It is a monoclonal antibody acting <strong>against IL-5</strong>.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8739",
      "difficulty": "easy"
    },
    {
      "text": "A patient diagnosed with Churg-Strauss syndrome is started on Mepolizumab. This drug acts against:",
      "choices": [
        {
          "id": 1,
          "text": "IgE"
        },
        {
          "id": 2,
          "text": "IgA"
        },
        {
          "id": 3,
          "text": "IL-5"
        },
        {
          "id": 4,
          "text": "IL-12"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Mepolizumab </strong>is a monoclonal antibody <strong>against IL-5.&nbsp;</strong>It is indicated in:&nbsp;</p>\n<ul>\n<li>Selected (eosinophilic phenotype) patients with <strong>severe asthma</strong></li>\n<li>Churg-Strauss syndrome&nbsp;</li>\n<li>Hypereosinophilic syndrome&nbsp;</li>\n</ul>\n<p>IL-5 plays a pivotal role in <strong>eosinophilic inflammation</strong> and is also involved in eosinophil survival and priming.</p>\n<p>Monoclonal antibodies against IL-5 approved for asthma are:</p>\n<ul>\n<li>Mepolizumab</li>\n<li>Reslizumab</li>\n<li>Benralizumab</li>\n</ul><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;The FDA recently approved a new indication for the drug Mepolizumab for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood-related cause of the disease.&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:33555069,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;9&quot;:0,&quot;12&quot;:0,&quot;28&quot;:1}\">The FDA recently approved a new indication for the drug Mepolizumab for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood-related cause of the disease.</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4393",
      "difficulty": "medium"
    },
    {
      "text": "What is the thromboxane receptor antagonist used in the treatment of asthma?",
      "choices": [
        {
          "id": 1,
          "text": "Seratrodast"
        },
        {
          "id": 2,
          "text": "Rimanobant"
        },
        {
          "id": 3,
          "text": "Sacubitril"
        },
        {
          "id": 4,
          "text": "Roflumilast"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Seratrodast </strong>is a<strong> thromboxane receptor antagonist </strong>indicated for use in<strong> long term prophylaxis of asthma</strong>. It is available and approved in India.</p>\n<p>Option B- <strong>Rimonabant</strong> is a <strong>cannabinoid receptor antagonist</strong> that was investigated for weight gain but now withdrawn due to adverse psychological effects&nbsp;</p>\n<p>Option C- <strong>Sacubitril</strong> is a <strong>neprilysin inhibitor</strong> approved in fixed-dose combination with valsartan for <strong>heart failure</strong> patients.</p>\n<p>Option D- <strong>Roflumilast</strong> is a <strong>phosphodiesterase 4 inhibitor</strong> which reduces eosinophil infiltration and inhibits inflammatory cell ,effective against smoke induced inflammation and emphysema.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7445",
      "difficulty": "hard"
    },
    {
      "text": "In a case of acute exacerbation of asthma, salbutamol was given, however, no improvement was noticed. Intravenous corticosteroids and aminophylline were given and the condition improved. What is the probable mechanism by which the corticosteroids would have improved the condition?",
      "choices": [
        {
          "id": 1,
          "text": "Corticosteroids increase bronchial responsiveness to salbutamol"
        },
        {
          "id": 2,
          "text": "Corticosteroids cause direct bronchodilatation when used with xanthines"
        },
        {
          "id": 3,
          "text": "Corticosteroids indirectly increase the effect of xanthines on adenosine receptor"
        },
        {
          "id": 4,
          "text": "Corticosteroids increase mucociliary clearance"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Corticosteroids</strong> improved the condition by <strong>increasing </strong>the <strong>airway&nbsp;responsiveness</strong> to<strong> salbutamol</strong>.</p>\n<p>Mechanism of action of corticosteroids in an acute asthma attack:</p>\n<ul>\n<li>Increases responsiveness to &beta;-2 agonists</li>\n<li>Decreases mucous secretion</li>\n<li>Decreases inflammatory cell response.</li>\n</ul>\n<p><strong>Steroids increase</strong> the <strong>transcription of &beta;-2 receptor genes</strong> and hence increases responsiveness to &beta;-2 agonists.</p>\n<p><strong>&beta;-2 agonists</strong> increase the effect of steroids by <strong>enhancing</strong> the <strong>action</strong> of <strong>glucocorticoid receptors.</strong></p>\n<p>Theophylline increases the effects of steroids by activating&nbsp;the enzyme histone deacetylase which is the target for steroids as well.</p>\n<p>Note: As per recent GINA 2021 guidelines, aminophyllines are no longer preferred in the management of acute severe asthma due to their low efficacy and poor safety profile.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9236",
      "difficulty": "medium"
    },
    {
      "text": "A patient has had 2 acute exacerbations of asthma over the span of 1-month despite being on therapy. Which of the following is a systemic steroid that can be used to treat her?",
      "choices": [
        {
          "id": 1,
          "text": "Ciclesonide"
        },
        {
          "id": 2,
          "text": "Beclomethasone"
        },
        {
          "id": 3,
          "text": "Prednisolone"
        },
        {
          "id": 4,
          "text": "Budesonide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Prednisolone </strong>is a <strong>systemic steroid </strong>used for <strong>maintenance therapy </strong>after an acute exacerbation of asthma.</p>\n<p>Intravenous corticosteroids such as hydrocortisone are indicated if the lung function is predicted to be &lt;30% or if there's poor response to nebulized &beta;<sub>2&nbsp;</sub>agonists. After the exacerbation, oral predisolone can be substituted with maximal beneficial effect at 30-40mg daily.</p>\n<p><strong>Inhaled corticosteroids</strong> commonly used in asthma are:</p>\n<ul>\n<li>Beclomethasone dipropionate</li>\n<li>Budesonide</li>\n<li>Ciclesonide</li>\n<li>Fluticasone</li>\n<li>Mometasone</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8743",
      "difficulty": "medium"
    },
    {
      "text": "An asthmatic patient presented to the ER with dyspnea and wheezing. Intake of which of the following is unlikely to have precipitated this?",
      "choices": [
        {
          "id": 1,
          "text": "Phenylbutazone"
        },
        {
          "id": 2,
          "text": "Naproxen"
        },
        {
          "id": 3,
          "text": "Caffeine"
        },
        {
          "id": 4,
          "text": "Aspirin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given clinical scenario is suggestive of an<strong> acute exacerbation</strong> of <strong>asthma</strong>. Caffeine&nbsp;does not precipitate this.</p>\n<p><strong>Caffeine</strong> is a <strong>dietary xanthine</strong> similar in structure to <strong>methylxanthines</strong>&nbsp;(theophylline) which are used as adjuvants in the <strong>treatment</strong> of asthma.&nbsp;</p>\n<p><strong>NSAIDs</strong> (like phenylbutazone, naproxen, and aspirin) inhibit the cyclooxygenase pathway thereby diverting arachidonic acid towards the lipoxygenase pathway. This <strong>increases</strong> the level of<strong> pro-inflammatory leukotrienes</strong> and can<strong> precipitate</strong> an <strong>acute asthma</strong> attack.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8744",
      "difficulty": "medium"
    },
    {
      "text": "A patient with mild episodic asthma is prescribed daily low-dose inhaled budesonide therapy. Which of the following conditions is he not at increased risk of developing?",
      "choices": [
        {
          "id": 1,
          "text": "Dysphonia"
        },
        {
          "id": 2,
          "text": "Pulmonary TB"
        },
        {
          "id": 3,
          "text": "Oropharyngeal candidiasis"
        },
        {
          "id": 4,
          "text": "Carcinoma of lung"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Inhaled corticosteroids&nbsp;</strong>(ICS)&nbsp;like <strong>budesonide</strong> do not increase the risk of developing carcinoma of the lung.</p>\n<p>Common problems with the use of ICS:&nbsp;</p>\n<ul>\n<li><strong>Hoarseness</strong>&nbsp;of voice</li>\n<li>Weakness of voice (<strong>dysphonia</strong>)</li>\n<li>Increased risk of bacterial and mycobacterial lung <strong>infection</strong></li>\n<li>Oropharyngeal <strong>candidiasis</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8745",
      "difficulty": "medium"
    },
    {
      "text": "An elderly man with a 30-year history of smoking complains of breathing difficulty. A diagnosis of COPD is made, and treatment with a long-acting muscarinic antagonist is initiated.  Which of the following will you not prescribe?",
      "choices": [
        {
          "id": 1,
          "text": "Glycopyrronium"
        },
        {
          "id": 2,
          "text": "Umeclidinium"
        },
        {
          "id": 3,
          "text": "Ipratropium"
        },
        {
          "id": 4,
          "text": "Tiotropium"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Ipratropium</strong> is a <strong>short-acting muscarinic antagonist&nbsp;</strong>which is not used for the long-term management of COPD. It can be used to treat <strong>acute exacerbations.</strong></p>\n<p>The long-acting muscarinic antagonists (<strong>LAMAs</strong>) are:</p>\n<ul>\n<li>Tiotropium</li>\n<li>Glycopyrronium&nbsp;</li>\n<li>Umeclidinium</li>\n<li>Aclidinium</li>\n</ul><hr><h3>Related Pearl: Ipratropium vs Tiotropium</h3><table>\n<tbody>\n<tr>\n<td><span>&nbsp;</span></td>\n<td>\n<p><span><strong>Ipratropium</strong></span></p>\n</td>\n<td>\n<p><span><strong>Tiotropium </strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Duration of action</strong></span></p>\n</td>\n<td>\n<p><span>Short</span></p>\n</td>\n<td>\n<p><span>Long</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Frequency of administration</strong></span></p>\n</td>\n<td>\n<p><span>3-4 times/day</span></p>\n</td>\n<td>\n<p><span>Once daily</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Antimuscarinic action</strong></span></p>\n</td>\n<td>\n<p><span>Non-selective</span></p>\n</td>\n<td>\n<p><span>Relatively selective for M1 and M3 receptors</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Paradoxical broncho</strong></span></p>\n<p><span><strong>constriction</strong></span></p>\n</td>\n<td>\n<p><span>Present *</span></p>\n</td>\n<td>\n<p><span>Absent</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>*Attributed to the nebulizer solution and other additives added. Blockade of prejunctional M2 receptors that normally inhibit acetylcholine release also can contribute.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4392",
      "difficulty": "medium"
    },
    {
      "text": "Inhalational anticholinergics the mainstay of treatment in:",
      "choices": [
        {
          "id": 1,
          "text": "Asthma"
        },
        {
          "id": 2,
          "text": "COPD"
        },
        {
          "id": 3,
          "text": "Both a and b"
        },
        {
          "id": 4,
          "text": "Status asthmaticus"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Inhalational anticholinergics</strong> are the mainstay for the treatment of <strong>COPD</strong>.</p>\n<p><strong>Ipratropium</strong> is as <strong>effective</strong> as albuterol in patients with COPD.<strong> Longer-acting antimuscarinic</strong> agents, including tiotropium, aclidinium, and umeclidinium, are approved for maintenance therapy of <strong>COPD.</strong></p>\n<p>Anticholinergics are less effective than&nbsp;&beta;-2 agonists as bronchodilators in asthma and are not the mainstay in the treatment of asthma.</p><hr><h3>Related Pearl: Ipratropium vs Tiotropium</h3><table>\n<tbody>\n<tr>\n<td><span>&nbsp;</span></td>\n<td>\n<p><span><strong>Ipratropium</strong></span></p>\n</td>\n<td>\n<p><span><strong>Tiotropium </strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Duration of action</strong></span></p>\n</td>\n<td>\n<p><span>Short</span></p>\n</td>\n<td>\n<p><span>Long</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Frequency of administration</strong></span></p>\n</td>\n<td>\n<p><span>3-4 times/day</span></p>\n</td>\n<td>\n<p><span>Once daily</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Antimuscarinic action</strong></span></p>\n</td>\n<td>\n<p><span>Non-selective</span></p>\n</td>\n<td>\n<p><span>Relatively selective for M1 and M3 receptors</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Paradoxical broncho</strong></span></p>\n<p><span><strong>constriction</strong></span></p>\n</td>\n<td>\n<p><span>Present *</span></p>\n</td>\n<td>\n<p><span>Absent</span></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>*Attributed to the nebulizer solution and other additives added. Blockade of prejunctional M2 receptors that normally inhibit acetylcholine release also can contribute.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8735",
      "difficulty": "medium"
    },
    {
      "text": "A chronic obstructive pulmonary disease (COPD) patient requires a step-up in therapy due to symptom persistence.  Which PDE-4 inhibitor can you prescribe as an add-on drug to his treatment regimen?",
      "choices": [
        {
          "id": 1,
          "text": "Seratrodast"
        },
        {
          "id": 2,
          "text": "Roflumilast"
        },
        {
          "id": 3,
          "text": "Zileuton"
        },
        {
          "id": 4,
          "text": "Nedocromil"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Roflumilast </strong>is a <strong>PDE-4 selective inhibitor </strong>approved for use in<strong> COPD.&nbsp;</strong></p>\n<p>PDE-4 is the major isoform present in inflammatory cells and its inhibition results in higher <strong>anti-inflammatory</strong> effects.&nbsp;</p>\n<p>Option A:&nbsp;<strong>Seratrodast</strong> is a <strong>thromboxane receptor antagonist</strong> used in the prophylaxis of asthma. It decreases the bronchial hypersensitivity caused by thromboxane.&nbsp;</p>\n<p>Option C:&nbsp;<strong>Zileuton</strong> is a <strong>lipoxygenase inhibitor</strong> that can be used in the treatment of asthma.</p>\n<p>Option D:&nbsp;<strong>Nedocromil</strong> is a <strong>mast cell stabilizer</strong> indicated in the prophylaxis of asthma.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4391",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs are antitussives?<div class='question-desc-html'><ol>\n<li>Dextromethorphan</li>\n<li>Morphine</li>\n<li>Guaifenesin</li>\n<li>Carbocysteine</li>\n<li>Gabapentin</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1, 2 and 4"
        },
        {
          "id": 2,
          "text": "1, 2 and 5"
        },
        {
          "id": 3,
          "text": "3 and 5"
        },
        {
          "id": 4,
          "text": "3 and 4"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Dextromethorphan, morphine,</strong> and <strong>gabapentin</strong> are all&nbsp;<strong>antitussives</strong>.</p>\n<p><strong>Dextromethorphan</strong> is an NMDA receptor antagonist that <strong>suppresses</strong> the <strong>cough center.</strong></p>\n<p>Opiates like <strong>morphine</strong>&nbsp;have a <strong>central</strong> mechanism of action on the medullary <strong>cough center</strong> and are indicated for intractable cough associated with bronchial carcinoma.&nbsp;</p>\n<p><strong>Gabapentin</strong> and pregabalin are <strong>GABA analogs</strong> that&nbsp;have been shown to benefit <strong>chronic idiopathic cough</strong> involving neural hypersensitivity.</p>\n<p><strong>Guaifenesin</strong> is an <strong>expectorant</strong> that is taken orally.</p>\n<p><strong>Carbocysteine</strong> is a <strong>mucolytic</strong> that&nbsp;reduces the disulfide bridges that bind glycoproteins to other proteins, such as albumin and secretory IgA. It is also taken orally and helps reduce the viscosity of sputum.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8747",
      "difficulty": "medium"
    },
    {
      "text": "A known case of CREST syndrome presents with dyspnea. On auscultation, a Graham-Steele murmur is heard. On further investigation, her pulmonary artery pressure is found to be 28 mm Hg. Which drug will you use to manage her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Non selective PDE inhibitors"
        },
        {
          "id": 2,
          "text": "Lipoxygenase inhibitors"
        },
        {
          "id": 3,
          "text": "Selective PDE-5 inhibitors"
        },
        {
          "id": 4,
          "text": "Cyclo-oxygenase inhibitors"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The clinical scenario points to a diagnosis of <strong>pulmonary artery hypertension </strong>(pulmonary artery pressure &gt; 20mmHg) which can be managed using<strong> selective PDE-5 inhibitors.</strong></p>\n<p>Inhibition of PDE-5 in the pulmonary bed leads to a reduction in the hydrolysis of cGMP which causes pulmonary vasodilation.</p>\n<p><strong>Sildenafil </strong>and<strong>&nbsp;tadalafil</strong> are the PDE-5 inhibitors approved for use in PAH.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8750",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following groups does riociguat belong to?",
      "choices": [
        {
          "id": 1,
          "text": "Soluble guanylate cyclase stimulator"
        },
        {
          "id": 2,
          "text": "Soluble guanylate cyclase inhibitor"
        },
        {
          "id": 3,
          "text": "Soluble adenylate cyclase stimulator"
        },
        {
          "id": 4,
          "text": "Soluble adenylate cyclase inhibitor"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong><strong>Riociguat </strong></strong>is a<strong><strong> soluble guanylate&nbsp;</strong></strong><strong>cyclase stimulator (sGC)</strong>, indicated in the treatment of <strong>pulmonary artery hypertension.</strong></p>\n<p>Riociguat increases the sensitivity of nitric oxide to sGC and also directly stimulates the sGC enzyme resulting in <strong>increased formation of cGMP</strong>. This leads to <strong>relaxation</strong> in the <strong>pulmonary vasculature.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8751",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs is a prostacyclin analog that can be added to the treatment regimen of a patient with pulmonary artery hypertension?",
      "choices": [
        {
          "id": 1,
          "text": "Sildenafil"
        },
        {
          "id": 2,
          "text": "Misoprostol"
        },
        {
          "id": 3,
          "text": "Dinoprost"
        },
        {
          "id": 4,
          "text": "Iloprost"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Iloprost </strong>is a<strong> prostacyclin analog </strong>indicated in the management of <strong>pulmonary artery hypertension</strong>. It falls under the category of&nbsp;IP receptor (prostacyclin receptor) agonists.</p>\n<p class=\"p1\">Other drugs falling under the category of <strong>IP receptor agonists</strong> are:</p>\n<ul>\n<li class=\"p1\">\n<p class=\"p1\">Epoprostenol</p>\n</li>\n<li class=\"p1\">\n<p class=\"p1\">Treprostinil</p>\n</li>\n<li class=\"p1\">\n<p class=\"p1\">Iloprost</p>\n</li>\n<li class=\"p1\">\n<p class=\"p1\">Selexipag</p>\n</li>\n</ul>\n<p>Option A: Sildenafil is a PDE-5 inhibitor.&nbsp;</p>\n<p class=\"p1\">Option B: Misoprostol is a synthetic PGE1 analog.&nbsp;</p>\n<p>Option C: Dinoprost is a natural PGF2-alpha preparation. It should&nbsp;not be confused with dinoprostone which is a synthetic analogue of PGE2.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8748",
      "difficulty": "medium"
    },
    {
      "text": "Which is a selective endothelin receptor A antagonist used in the management of pulmonary artery hypertension?",
      "choices": [
        {
          "id": 1,
          "text": "Bosentan"
        },
        {
          "id": 2,
          "text": "Ambrisentan"
        },
        {
          "id": 3,
          "text": "Tezosentan"
        },
        {
          "id": 4,
          "text": "Macitentan"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Ambrisentan</strong> is a <strong>selective</strong> endothelin receptor A (<strong>ET-A</strong>)<strong> antagonist</strong>&nbsp;which is used in the management of pulmonary artery hypertension (PAH).</p>\n<p>Bosentan, tezosentan, and macitantan are&nbsp;non-selective (ET-A and ET-B) endothelin receptor antagonists.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8749",
      "difficulty": "hard"
    },
    {
      "text": "Dornase alfa is indicated in which of the following patients?<div class='question-desc-html'><ol>\n<li>A 30-year-old man with bronchial asthma</li>\n<li>A 72-year-old man with COPD</li>\n<li>A 19-year-old boy with cystic fibrosis</li>\n<li>A 25-year-old woman with pulmonary artery hypertension</li>\n<li>A newborn with refractory atelectasis</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "Only 3"
        },
        {
          "id": 2,
          "text": "2, 4 and 5"
        },
        {
          "id": 3,
          "text": "3 and 5"
        },
        {
          "id": 4,
          "text": "1, 2 and 3"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Dornase alfa </strong>is indicated in patients with <strong>cystic fibrosis</strong> and as a rescue treatment for<strong> refractory atelectasis </strong>in newborn and pediatric populations.</p>\n<p>Dornase alfa is a <strong>recombinant DNase 1 </strong>that<strong>&nbsp;</strong>digests neutrophil DNA deposited in the pulmonary mucus thereby <strong>reducing mucosal viscoelasticity</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4381",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following should not be prescribed with theophylline?",
      "choices": [
        {
          "id": 1,
          "text": "Erythromycin"
        },
        {
          "id": 2,
          "text": "Cefotaxime"
        },
        {
          "id": 3,
          "text": "Cotrimoxazole"
        },
        {
          "id": 4,
          "text": "Amoxicillin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Erythromycin</strong>&nbsp;should not be prescribed with theophylline.</p>\n<p>Theophylline is mainly metabolized by CYP1A2 in the liver.&nbsp;Erythromycin <strong>inhibits CYP1A2</strong> and thereby <strong>decreases</strong> the <strong>clearance</strong> of<strong> theophylline</strong>.</p>\n<p>Factors decreasing the clearance of theophylline are:</p>\n<ul>\n<li>Drugs - erythromycin, cimetidine, ciprofloxacin,&nbsp;allopurinol, fluvoxamine, zileuton, zafirlukast</li>\n<li>Congestive heart failure</li>\n<li>Liver disease</li>\n<li>Pneumonia</li>\n<li>Viral infection and vaccination</li>\n<li>High-carbohydrate diet</li>\n<li>Old age</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0804",
      "difficulty": "easy"
    },
    {
      "text": "If codiene is coming to the market in combination with dextromethorphan as an anti-tussive, this combination _______",
      "choices": [
        {
          "id": 1,
          "text": "Should not be used due to risk of addiction"
        },
        {
          "id": 2,
          "text": "Can be used as both have different mechanism of action"
        },
        {
          "id": 3,
          "text": "Should not be used as it is  irrational"
        },
        {
          "id": 4,
          "text": "Can be used to treat cough effectively"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>It is an <strong>irrational drug combination</strong> and should not be given.</p>\n<p><strong>Codeine</strong> is an <strong>opioid analgesic</strong> having specific antitussive action while <strong>dextromethorphan</strong> is a <strong>centrally</strong> active <strong>NMDA</strong> receptor antagonist that may be effective as an antitussive. Both are <strong>centrally acting antitussives</strong>, and do not provide any added advantage when combined. Hence it is an irrational drug combination.</p>\n<p><strong>Rational fixed-dose combination </strong>drugs for the treatment of cough usually contain:</p>\n<ul>\n<li>A centrally acting anti-tussive (either codeine or dextromethorphan; not both), with</li>\n<li>Antihistamines, decongestants and expectorants.</li>\n</ul>\n<p>Option A - Both of these drugs carry a <strong>risk of addiction,</strong> but it is not the reason to not give the drug. The main reason is that the combination is irrational.</p>\n<p>Options B &amp; D - Both codeine and dextromethorphan have<strong> different mechanisms of action</strong>&nbsp;and<strong> can treat cough effectively.</strong> However, the combination of two centrally acting antitussives does not provide any added advantage compared to using one drug alone. Hence, the combination is irrational.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD6617",
      "difficulty": "medium"
    }
  ]
}